Koutif Therapeutics is advancing discoveries from researchers at the University of Pittsburgh. Their academic founders are developing an inhibitor of E3 ligase Fbxo3, which is implicated in the pathogenesis of inflammatory conditions such as neuropathic pain, bronchiolitis obliterans syndrome, irritable bowel disease, chronic obstructive pulmonarydisease, rheumatoid arthritis, and acute lung injury.

Biotechnology

Clinical Trials

Health Care

Therapeutics

Koutif Therapeutics

Koutif Therapeutics' headquarters in Cleveland, OH, United States

Description

People

Jobs